Videos

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

In the second segment of the interview, Gilead’s Gelezinuas and SenGupta discuss the areas of unmet HIV therapy needs, cure research, and the benefits of a virtual conference.

How a sexually-transmitted virus is hindered by limited marketing, and how its stigmas compare to those developing around COVID-19.

Gilead provides some important information on this investigational therapy.

A study looking at PrEP population obstacles shows men who have sex with men are more likely to not seek out information nor access to prophylaxis.

Dr. Marc Pitasi, epidemiologist, discusses facilitators of routine HIV screening among primary care physicians.

A discussion around new data presented at AIDS 2020 which shows statewide strategies are breaking down barriers.

Uncovering interesting findings regarding patients' PrEP regimen.

How much does the current virus crisis share in common with early HIV outbreak scare?

A look at the BRIGHTE study data which evidenced the recently FDA-approved add-on agent.

Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.

How the inflammatory-based syndrome is affecting US children during the COVID-19 pandemic.

A discussion on how the pediatric inflammatory syndrome has begun to affect the US months into the pandemic.

A discussion with a Yale expert on what new CDC data shows.

Judith Feinberg, MD, FIDSA, describes ongoing investigation into the immune response from COVID-19.

A brief overview of our top stories.

Jonathan Spero, MD, discusses workplace safety in the time of SARS-CoV-2.

Recent concerns have been raised about a spike protein mutation in SARS-CoV-2. Are these fears grounded?

Judith Feinberg, MD, FIDSA, describes surprising outcomes in many COVID-19 cases among people living with HIV.

The status of emergency departments in the city during the pandemic's migration west.

Bradley Sherman, MD, shares insight as to what goes into a respiratory ventilator recovery unit.

A brief summary of the latest news.

Dr. Luwy Musey, executive director in biologics, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.

A look at how the state became a belated hotspot, and what may help reduce future infection growth.

A brief on today's top ID news.

In a joint-interview, we discuss the PCV pipeline with Dr. Luwy Musey (of Merck & Co.) and Dr. Steven Pelton.

Video briefing on the day's top infectious disease news.

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.